Polaris Capital Management LLC Invests $32.69 Million in Lantheus Holdings, Inc. $LNTH

Polaris Capital Management LLC acquired a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 637,300 shares of the medical equipment provider’s stock, valued at approximately $32,687,000. Lantheus accounts for about 2.1% of Polaris Capital Management LLC’s holdings, making the stock its 21st biggest position. Polaris Capital Management LLC owned about 0.94% of Lantheus at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of the company. Strs Ohio acquired a new stake in Lantheus in the 1st quarter valued at about $4,529,000. Silverberg Bernstein Capital Management LLC raised its holdings in shares of Lantheus by 28.6% in the 2nd quarter. Silverberg Bernstein Capital Management LLC now owns 27,179 shares of the medical equipment provider’s stock worth $2,225,000 after purchasing an additional 6,050 shares in the last quarter. Harbor Capital Advisors Inc. lifted its stake in Lantheus by 24.7% during the second quarter. Harbor Capital Advisors Inc. now owns 190,008 shares of the medical equipment provider’s stock valued at $15,554,000 after purchasing an additional 37,691 shares during the last quarter. Reinhart Partners LLC. boosted its holdings in Lantheus by 16.4% during the second quarter. Reinhart Partners LLC. now owns 1,403,659 shares of the medical equipment provider’s stock worth $114,905,000 after buying an additional 197,719 shares in the last quarter. Finally, Focus Financial Network Inc. grew its position in Lantheus by 4.0% in the second quarter. Focus Financial Network Inc. now owns 3,576 shares of the medical equipment provider’s stock worth $293,000 after buying an additional 136 shares during the last quarter. 99.06% of the stock is owned by institutional investors and hedge funds.

Lantheus Stock Down 0.1%

Lantheus stock opened at $67.48 on Tuesday. Lantheus Holdings, Inc. has a twelve month low of $47.25 and a twelve month high of $111.29. The company has a debt-to-equity ratio of 0.51, a quick ratio of 2.49 and a current ratio of 2.67. The firm has a market cap of $4.47 billion, a PE ratio of 28.35 and a beta of -0.11. The firm’s 50 day moving average price is $61.36 and its two-hundred day moving average price is $61.20.

Lantheus (NASDAQ:LNTH) last issued its earnings results on Thursday, November 6th. The medical equipment provider reported $1.27 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.27. Lantheus had a net margin of 10.99% and a return on equity of 30.88%. The company had revenue of $384.01 million during the quarter, compared to analyst estimates of $363.42 million. During the same quarter last year, the business posted $1.70 EPS. The company’s revenue for the quarter was up 1.4% on a year-over-year basis. Lantheus has set its FY 2025 guidance at 5.500-5.650 EPS. On average, research analysts predict that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

LNTH has been the subject of a number of recent research reports. The Goldman Sachs Group set a $77.00 price objective on Lantheus and gave the company a “neutral” rating in a research report on Wednesday, October 8th. Weiss Ratings raised shares of Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, January 6th. Mizuho lifted their target price on shares of Lantheus from $60.00 to $72.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 17th. Truist Financial upped their price target on shares of Lantheus from $80.00 to $82.00 and gave the company a “buy” rating in a research report on Thursday, December 18th. Finally, B. Riley lowered their price objective on shares of Lantheus from $109.00 to $84.00 and set a “buy” rating on the stock in a research report on Tuesday, September 16th. Five investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $78.00.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.